Range | 40–59 | 38–64 | |
Mean ± SD | 49.5 ± 4.9 | 50.6 ± 7.2 | |
Median | 49 | 50 | |
≤45 years | 4 (19%) | 4 (21.1%) | |
>45 years | 17 (81%) | 15 (78.9%) | |
8 (42.1%) | |||
Premenopausal | 11 (52.4%) | 11 (57.9%) | |
Postmenopausal | 10 (47.6%) | ||
4 (21.1) | |||
0 | 5 (23.8%) | 10 (52.6%) | |
1 | 11 (52.4%) | 5 (26.3%) | |
2 | 5 (23.8%) | ||
1.824 ± 0.18 | 1.795 ± 0.16 | ||
Mean ± SD | |||
Bone | 14 (66.7%) | 13 (68.4%) | |
Lung | 7 (33.3%) | 7 (36.8%) | |
Liver | 11 (52.4%) | 9 (47.4%) | |
Brain | 6 (28.6%) | 5 (26.3%) | |
LNs | 2 (9.5%) | 1 (5.3%) | |
1 | 6 (28.6%) | 7 (36.8%) | |
2 | 8 (38.1%) | 6 (31.6%) | |
> or =3 | 7 (33.3%) | 6 (31.6%) | |
ER positive | 13 (61.9%) | 12 (63.2%) | |
PR positive | 12 (57.1%) | 8 (42.1%) | |
Her 2 positive | 4 (19%) | 5 (26.3%) | |
Triple negative | 5 (23.8%) | 4 (21.1%) | |
- | |||
• |
|||
2 | 8 (38.1%) | 10 (52.6%) | |
3 | 11 (52.4%) | 9 (47.4%) | |
4 | 2 (9.5%) | 0 (0%) | |
• |
|||
0 | 3 (14.3%) | 4 (21.1%) | |
1 | 7 (33.3%) | 6 (31.6%) | |
2 | 7 (33.3%) | 6 (31.6%) | |
3 | 4 (19 %) | 3 (15.8%) | |
• |
|||
1 | 2 (9.5%) | 1 (5.3%) | |
2 | 11 (52.4%) | 12 (63.2%) | |
3 | 8 (38.1%) | 6 (31.6%) | |
- |
|||
Infiltrating duct carcinoma | 17 (81%) | 17 (89.5%) | |
Infiltrating lobular carcinoma | 4 (19%) | 2 (10.5%) |
- | 13 (61.9) | 7 (33.3) | 4 (19) | 2 (9.5) | 9 (47.3) | 7 (36.8) | 2 (10.5) | 0 | |||
- | 12 (57.1) | 8 (38) | 3 (14.2) | 1 (4.7) | 8 (42.1) | 6 (31.5) | 2 (10.5) | 0 | |||
- | 7 (33.3) | 5 (23.8) | 1 (4.7) | 1 (4.7) | 4 (21) | 4 (21) | 0 | 0 | |||
- | 7 (33.3) | 4 (19) | 3 (14.2) | 0 | 4 (21) | 2 (10.5) | 2 (10.5) | 0 | |||
- | 9 (42.8) | 4 (19) | 2 (9.5) | 3 (14.2) | 6 (31.5) | 5 (26.3) | 1 (5.2) | 0 | |||
- | 7 (33.3) | 3 (14.2) | 3 (14.2) | 1 (4.7) | 4 (21) | 3 (15.7) | 1 (5.2) | 0 | |||
- | |||||||||||
Anemia | 10 (47.6) | 6 (28.5) | 3 (14.2) | 1 (4.7) | 4 (21) | 4 (21) | 0 | 0 | |||
Neutropenia | 8 (38) | 3 (14.2) | 4 (19) | 1 (4.7) | 4 (21) | 3 (15.7) | 1 (5.2) | 0 | |||
Thrombocytopenia | 7 (33.3) | 4 (19) | 3 (14.2) | 0 | 2 (10.5) | 2 (10.5) | 0 | 0 |
≤45 years | 7 (17.5) | 8 (20) | 4 (19) | 4 (19) | 3 (15.7) | 4 (21) | |||
>45 years | 1 (2.5) | 24 (60) | 0 | 13 (61.9) | 1 (5.2) | 11 (57.8) | |||
Premenopausal | 7 (17.5) | 8 (20) | 4 (19) | 4 (19) | 3 (15.7) | 4 (21) | |||
Postmenopausal | 12 (30) | 13 (32.5) | 7 (33.3) | 6 (28.5) | 5 (26.3) | 7 (36.8) | |||
1 | 3 (7.5) | 0 | 2 (9.5) | 0 | 1 (5.2) | 0 | |||
2 | 5 (12.5) | 18 (45) | 2 (9.5) | 9 (42.8) | 3 (15.7) | 9 (47.3) | |||
3 | 7 (17.5) | 7 (17.5) | 4 (19) | 4 (19) | 3 (15.7) | 3 (15.7) | |||
No | 14 (35) | 17 (42.5) | 8 (38) | 8 (38) | 6 (31.5) | 9 (47.3) | |||
Yes | 1 (2.5) | 8 (20) | 0 | 5 (23.8) | 3 (15.7) | 1 (5.2) | |||
1 | 10 (25) | 3 (7.5) | 4 (19) | 1 (4.7) | 6 (31.5) | 2 (10.5) | |||
2 | 4 (10) | 10 (25) | 3 (14.2) | 5 (23.8) | 1 (5.2) | 5 (26.3) | |||
≥ 3 | 1 (2.5) | 12 (30) | 1 (4.7) | 7 (33.3) | 0 | 5 (26.3) | |||
First | 14 (35) | 11 (27.5) | 7 (33.3) | 6 (28.5) | 7 (36.8) | 5 (26.3) | |||
Second | 1 (2.5) | 9 (22.5) | 1 (4.7) | 5 (23.8) | 0 | 4 (21) | |||
Third or more | 0 | 5 (12.5) | 0 | 2 (9.5) | 0 | 3 (15.7) |
No | 3 (14.3%) | 2 (10.5%) | |
Anthracycline/taxanes | 13 (61.9%) | 11 (57.9%) | |
Anthracycline + 5-FU | 5 (23.8%) | 6 (31.6%) | |
14 (66.7%) | 11 (57.9%) | ||
- |
|||
Taxanes ± carboplatin | 2 (9.5%) | 3 (15.8%) | |
Navelbine ± FU | 2 (9.5%) | 4 (21.1%) | |
Gem–cisplatin/carboplatin | 3 (14.3%) | 2 (10.5%) | |
- Palliative HT | 11 (52.4%) | 10 (52.6%) | |
First | 14 (66.7%) | 9 (47.4%) | |
Second | 5 (23.8%) | 6 (31.6%) | |
Third or more | 2 (9.5%) | 4 (21.1%) | |
Median no. of cycles (range) | 6 (2–8) | 8 (4–10) | |
Dose reduction | 12 (57.1%) | 1 (5.3%) | |
Cycle delay | 11 (52.3%) | 4 (21.1%) |
- | 1 (4.7) | 2 (10.5) | ||
- | 8 (38) | 7 (36.8) | ||
- | 3 (14.2) | 4 (21) | ||
- | 10 (47.6) | 8 (42.1) | ||
- | 8.16 ± 0.63 | 8.98 ± 0.75 | ||
- | 10.1 | 10 | ||
- | 11.94 ± 0.754 | 11.24± 0.665 | ||
- | 13.1 | 13 |